Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$190.01M

FY 2025 · Annual

Investing Cash Flow

$103.77M

FY 2025 · Annual

-21.2% YoY

Financing Cash Flow

$148,000.00

FY 2025 · Annual

-99.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
Deferred Income Tax3.15M0000
Stock-Based Compensation29.24M31.01M39.41M43.92M37.06M
Change in Working Capital(3.39M)6.08M13.46M1.92M(8.3M)
Accounts Receivables00000
Inventory00000
Accounts Payables(4.83M)9.67M000
Other Working Capital1.44M(3.6M)13.46M1.92M(8.3M)
Other Non-Cash Items13.53M370K(9.28M)(6.19M)(6.68M)
Operating Cash Flow(121.16M)(178.14M)(194.92M)(209.72M)(190.01M)
Capital Expenditures(7.72M)(8.62M)(16.47M)(5.86M)(440K)
Acquisitions (Net)95K42.73M000
Purchases of Investments(245.88M)(376.33M)(390.92M)(245.89M)(276.55M)
Sales of Investments272.44M272.89M309.33M383.45M380.76M
Other Investing Activities(95K)0000
Investing Cash Flow18.85M(69.33M)(98.07M)131.71M103.77M
Debt Repayment201K172K139K00
Common Stock Issued37.68M155.34M208.39M185.74M0
Common Stock Repurchased0(47K)00(67K)
Dividends Paid00000
Other Financing Activities(201K)(172K)(132K)0215K
Financing Cash Flow37.68M155.29M208.4M185.74M148K
Effect of Forex Changes00000
Net Change in Cash(64.63M)(92.18M)(84.58M)107.72M(86.1M)
Free Cash Flow(128.88M)(186.76M)(211.39M)(215.59M)(190.45M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$223.1M
+ D&A$11.0M
+ Stock-Based Comp$37.1M
+ Deferred Tax$0
- Working Capital-$8.3M
- Other Non-Cash-$6.7M
= Operating Cash Flow-$190.0M
- Capex-$440.0K
= Free Cash Flow-$190.5M

Analysis

FY2025 free cash flow is -$190.5M. FCF conversion is 85.4% of net income. Operating cash flow was -$190.0M, with capex of -$440.0K. The largest bridge item is Stock-Based Comp at $37.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
SC 13G/ASC 13G/A filingOct 30, 2026

Does RCKT generate free cash flow?

Rocket Pharmaceuticals, Inc. (RCKT) generated -$190.45M of free cash flow in fiscal 2025.

How much operating cash flow does RCKT produce?

Operating cash flow was -$190.01M, before capital expenditures of $440,000.00.